Conference programme

Please download the BCH 2025 scientific program here
Please download the BCH for nurses scientific program here
Please download the ABSTRACT BOOK here
BCH 2025 conference has been determined as compliant with MedTech Europe Code of Ethical Business Practice and EFPIA Code of Practice, event number EMT-24-00770.

24th April
14:00-15:00	Registration, Hilton Tallinn Park Hotel (F.R. Kreutzwaldi 23)
15:00-15:05	Opening of the Conference
15:05-16:30	Scientific Session I: Migration and Medicine Moderators: Mari Punab, Skirmante Černauskiene
15:05-15:30	„Past migrations and present-day variation in NCD susceptibilities” - Anders Eriksson, Tartu University, Estonia
15:30-15:50	„Health and healthcare needs of Ukrainian war refugees in Estonia” - Galina Opikova, Estonia
15:50-16:10	„Help for Ukrainian Hematology Patients in Vilnius University Hospital Santaros Klinikos“ - Milda Mikalonytė, Lithuania
16:10-16:30	„Impact of climate changes on infections“ - Bruno Saar, Estonia
16:30-17:00	Coffee break, exhibition
17:00-18:45	Scientific session II: Bleeding disorders Moderators: Jecko Thachil, Valdas Banys
17:00-17:40	„Why may patients with von Willebrand disease bleed?“ - Jecko Thachil, UK
17:40-18:00	„Overview and results of the von Willebrand disease genotype and phenotype study“ - Kazimieras Maneikis, Lithuania
18:00-18:15	„Diagnostic algorithm for von Willebrand disease“ - Marika Pikta, Estonia
18:15-18:30	„The Situation of Laboratory Diagnostics of Bleeding Disorders in Baltic States“ - Valdas Banys, Lithuania
18:30-18:45	„Management of mild/moderate hemophilia patient with atrial fibrillation and dilatative cardiomyopathy" - Kristīne Bernāte, Latvia
19:00	Welcome reception (foyer area of the venue, no live music/entertainment)

25th April
07:00-08:15	Fun & Run at Kadriorg Park (bus leaves at 06:50 in front of the Hilton Tallinn Park Hotel).
09:00-11:00	Scientific Session III: Malignant lymphomas Moderators: Lukas Kevlicius , Olga Rätsep
09:00-09:30	„Current and Emerging Treatments for Relapsed or Refractory Large B-cell Lymphoma" - Prof. Frederik Damm, Germany
09:30-09:45	„Polatuzumab vedotin with chemotherapy as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas: VUL SK experience“ - Tautvilė Smalinskaitė, Lithuania
09:45-10:00	„Epcoritamab in relapsed or refractory large B-cell lymphomas: Estonian experience“ - Renate Katsev, Estonia
10:00-10:15	„Early Clinical Efficacy of Place-of-Care Manufactured MB-CART19.1 Cell Therapy in Patients with Relapsed or Refractory CD19+ Lymphomas in a Real-World Setting, VUL SK” - Skirmantė Černauskienė, Lithuania
10:15-10:45	„Paradigm Shifts in Hodgkin Lymphoma Treatment" - Peter Borchmann, Germany
10:45-11:00	„Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma before autologous stem cell transplantation: VUL SK experience“ - Lukas Kevličius, Lithuania
11:00-11:30	Coffee break, exhibition
11:30-13:00	Scientific session IV: Acute myeloid leukaemia Moderators: Andrius Žučenka, Ain Kaare
11:30-12:00	Keynote lecture - „Management of acute myeloid leukaemia in 2024“ - Andrius Žučenka, Lithuania
12:00-12:20	„Lithuanian experience - Individualized therapy for R/R AML in Vilnius“ - Andrius Žučenka, Lithuania
12:20-12:40	„Hematopoietic stem cell transplantation in children with AML – Estonian experience“ - Triin Pohlak, Estonia
12:40-13:00	„Modern strategies in AML treatment: the role of CPX-351 and Latvian insights" - Arturs Uzars, Latvia
13:00-14:00	Lunch
13:00-14:00	Roche satellite session on Malignant Lymphomas Moderator: Renate Katsev „The role of bispecifics in third line treatment for diffuse large B-cell lymphoma with focus on Columvi® (glofitamab)" - Frederik Damm, Germany
14:00-15:30	Scientific session V: Acute lymphoblastic leukaemia Moderators: Goda Vaitkevičienė, Maarja Karu
14:00-14:30	Lecture „Blinatumomab in the Treatment of Acute Lymphoblastic Leukaemia“ - Anita Rijneveld, Netherlands
14:30-14:50	„Lithuanian experience of treatment with blinatumomab“ - Goda Vaitkevičienė, Lithuania
14:50-15:10	„Estonian experience of treatment with blinatumomab ” - Maarja Karu, Estonia
15:10-15:30	„Early Clinical Efficacy of Place-of-Care Manufactured MB-CART19.1 Cell Therapy in Patients with Relapsed or Refractory CD19+ ALL in a Real-World Setting, VUL SK” - Skirmantė Černauskienė, Lithuania
15:30-16:00	Coffee break, exhibition
16:00-17:50	Scientific session VI: Multiple Myeloma Moderators: Valdas Peceliunas, Diana Loigom
16:00-16:40	„MGUS and SMM: Results from the iStopMM study and  SMM risk stratification in relation to treatment“ - Sigrun Thorsteinsdottir, Iceland
16:40-16:55	„Upfront ASCT in Multiple Myeloma: Insights from Lithuania and Estonia parts in a real-world NMSG study“ - Vilmantė Vaitekėnaitė, Lithuania and Diana Loigom, Estonia
16:55-17:10	„Carfilzomib, lenalidomide, and dexamethasone Induction and consolidation with salvage autologous stem cell transplantation. Single centre experience“ - Vilmantė Vaitekėnaitė, Lithuania
17:10-17:50	„MRD driven treatment in Multiple Myeloma“ - Fredrik Schjesvold, Norway
17:50-18:05	„TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors Talquetamab and Teclistamab consolidation as part of first line treatment in transplant eligible multiple myeloma patients, Nordic Myeloma Study Group“ - Diana Loigom, Estonia
19:30	Conference dinner in Cruise Terminal of Tallinn Old City Harbour, Logi Str 4 (a surcharge applies) Buses leave in front of the Hilton Tallinn Park Hotel at 19:10

26th April
09:00-10:45	Scientific Session VII: Myeloproliferative Neoplasms Moderators: Dārta Balode, Maris Pärnat
09:00-09:40	„Risk assessment in MPN and managing high risk polycythemia vera“- Prof. Heinz Gisslinger, Austria
09:40-10:15	„Advances in myelofibrosis treatment“ - Tomasz Sacha, Poland
10:15-10:30	„Latvian experience - PV treatment with ropeginterferon alfa-2b“ - Dārta Balode, Latvia
10:30-10:45	„Overview of the Ph-negative chronic myeloproliferative neoplasms (MPN) in Estonia during 2019-2023“ - Halliki Kõdar, Estonia
10:45-11:00	Coffee break, exhibition
11:00-12:15	AstraZeneca satellite symposia - "Beyond the Blood: Exploring treatment approaches in CLL and PNH"
	Part I, moderator Iige Viigimaa
11:00-11:20	„CLL treatment landscape“ - Prof Clemens Wendtner, Germany
11:20-11:35	Discussion panel: Iige Viigimaa (Estonia), Andrius Degulys (Lithuania), Kristīne Bernāte (Latvia), Prof. Clemens Wendtner (Germany)
	Part II, moderator Andrius Degulys
11:35-12:05	„Messages from specialist: complement dysregulation in hematological diseases - what's on stake?" - Andrius Degulys, Prof. Laura Malinauskienė, Lithuania
12:05-12:15	Discussion panel: Iige Viigimaa (Estonia), Andrius Degulys (Lithuania), Kristīne Bernāte (Latvia), Prof. Laura Malinauskienė (Lithuania)
12:15-13:30	Scientific session VIII Moderators: Kadri Saks, Mari Punab
12:15-13:00	Rapid fire. Short presentations/ case studies from Baltic States Case of CNS GVHD - Milvyde Marija Tamutyte, Lithuania Successful Pregnancy Outcome in Essential Thrombocytaemia Patient After Multiple Miscarriages - Edward Laane, Estonia Thalassemia syndromes in children: Croatian experience - Jelena Roganovic, Croatia Development of Novel CAR-T Cell Therapies Against Cancer - Ana Shahpazir, Estonia The first molecularly confirmed patient with VEXAS syndrome in Estonia: a case report and outcome - Tiina Kahre, Estonia Genetic Profiling of Estonian Multiple Myeloma and Monoclonal gammopathy Patients at Diagnosis - Maria Keernik, Estonia Desmopressin responsiveness in von Willebrand disease patients - Laura Johanna Mettis, Estonia Results of capillary electrophoresis in the evaluation of hemoglobinopathies in non-endemic country - Marika Pikta, Estonia
13:05-13:30	„Comparator Report on Cancer in Europe - Focus on the Baltic States“ - Thomas Hofmarcher, Sweden
13:30	Final remarks, conference closing session